Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Erythropoiesis01:14

Erythropoiesis

6.5K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
6.5K
Erythropoiesis01:14

Erythropoiesis

3.9K
3.9K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.6K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026
Same author

Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia.

Blood neoplasia·2026
Same author

Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients.

Annals of hematology·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Isolated <i>KRAS</i> and <i>NRAS</i> mutations in adults with monocytosis and/or cytopenia(s).

Haematologica·2025
Same author

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study.

Cancer·2025
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Revisiting erythroleukemia.

Daniel A Arber1

  • 1Department of Pathology, University of Chicago, Chicago, Illinois, USA.

Current Opinion in Hematology
|November 23, 2016
PubMed
Summary
This summary is machine-generated.

The 2016 WHO classification revised erythroleukemia diagnosis, removing the erythroid/myeloid subtype. This change reclassifies many cases as myelodysplastic syndromes, impacting prognostic understanding.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.9K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Related Experiment Videos

Last Updated: Mar 11, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.9K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The 2016 World Health Organization (WHO) classification introduced significant changes to the diagnostic criteria for hematopoietic and lymphoid neoplasms.
  • Previously, acute erythroleukemia included an erythroid/myeloid subtype, a subcategory of acute myeloid leukemia, not otherwise specified.

Purpose of the Study:

  • To review the literature supporting the 2016 WHO classification changes for erythroleukemia.
  • To summarize recent findings on the clinical significance of these diagnostic alterations.

Main Methods:

  • Literature review of studies contributing to the 2016 WHO classification.
  • Analysis of recent research on erythroid predominance in myelodysplastic syndromes (MDSs) and erythroleukemia.

Main Results:

  • The 2016 WHO classification now recognizes only pure erythroid leukemia, eliminating the erythroid/myeloid subtype.
  • Cases previously classified as erythroid/myeloid acute erythroleukemia are now often reclassified under MDS, typically MDS with excess blasts, based on blast cell count.
  • Erythroid predominance (≥50% bone marrow erythroid cells) in MDS has a known negative prognostic impact.

Conclusions:

  • The revised classification clarifies diagnostic criteria for erythroleukemia.
  • Reclassifying erythroid/myeloid cases as MDS may obscure the prognostic significance of erythroid predominance in these patients.
  • Ongoing challenges remain in classifying erythroid-rich bone marrow disorders.